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 Abstract 
It is one of the best pharmaceutical dosage forms for those patients, they cannot take medicaments orally. 
Transdermal drug delivery system (TDDS) established itself as an integral part of novel drug delivery systems (NDDS). On 
the application of Transdermal patches, the delivery of the drug across dermis gives the systemic effect. TDDS is costly 
alternative to conventional formulation. It is also important due to its unique advantage. Controlled absorption, more 
uniform plasma levels, improved bioavailability, reduced side effects, painless and simple application and flexibility of 
terminating drug administration by simply removing the patch from the skin are some of the potential advantages of 
transdermal drug delivery. Development of controlled release transdermal dosage form is a complex process involving 
extensive efforts. This review article describes the methods of preparation of different types of transdermal patches. In 
addition, the various methods of evaluation of transdermal dosage form and Advance Development in TDDS have also 
been reviewed.  
Keywords: TDDS, NDDS, Transdermal Patches, Drug polymer, Permeation enhancers. 
1. Introduction  
Transdermal drug delivery is the non-invasive 
delivery of medications from the surface of skin-the largest 
and most accessible organ of human body- through its 
layers, to the circulatory system. TDDS offers many 
advantages over conventional injection and oral methods. It 
reduces the load that the oral route commonly places on the 
digestive tract and liver. It enhances patient compliance and 
minimizes harmful side effects of a drug caused from 
temporary overdose. Another advantage is convenience, 
especially notable in patches that require only once weekly 
application. Such a simple dosing regimen can aid in patient 
adherence to drug therapy.  
 
 
 
Designing and development of transdermal 
patches can be described as state of the art. The 
development of TDDS is multidisciplinary activity that 
encompasses fundamental feasibility A studies starting 
from the selection of drug molecule to the demonstration of 
sufficient drug flux in an ex vivo and in vivo model 
followed by fabrication of a drug delivery system that 
meets all the stringent needs that are specific to the drug 
molecule (physicochemical and stability factors), the 
patient (comfort and cosmetic appeal), the manufacturer 
(scale up and manufacturability) and most important the 
economy[1].  
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Fig1; Structure of Skin 
 
1.1 Transdermal Permeation  
Earlier skin was considered as an impermeable 
protective barrier, but later investigations were carried out 
which proved the utility of skin as a route for systemic 
administration [2]. Skin is the most intensive and readily 
accessible organ of the body as only a fraction of millimeter 
of tissue separates its surface from the underlying capillary 
network. The various steps involved in transport of drug 
from patch to systemic circulation are as follows [3-4]:  
 Diffusion of drug from drug reservoir to the rate 
controlling membrane. 
 Diffusion of drug from rate limiting membrane to stratum 
corneum.  
 Sorption by stratum corneum and penetration through 
viable epidermis. 
 Uptake of drug by capillary network in the dermal 
papillary layer.  
 
1.2 TDDS Classification Based On Their Technical 
Sophistication  
A) Rate pre-programmed drug delivery system  
B) Activation modulated drug delivery system  
C) Feedback regulated drug delivery system  
D) Carrier based drug delivery system  
 
A) Rate Pre Programmed Drug Delivery System  
It involves the system designs that deliver 
medicaments by controlling molecular diffusion of drug 
molecules across the skin barrier within or surrounding the 
delivery system.  
Polymer membrane permeation controlled drug 
delivery system-  
It involves the system in which the drug is 
enclosed within a drug reservoir. This is covered by the 
semi permeable membrane of polymer that regulates the 
release and having a specific permeability. There are some 
potential development with process of membrane 
permeation are as micro porous membrane permeation 
controlled gastrointestinal delivery device, gastric fluid 
resistance intestinal targeted controlled release 
gastrointestinal device and gel diffusion controlled drug 
delivery system.  
1-Polymer matrix diffusion controlled drug delivery 
system 
It is developed by dispersing drug particles in 
carrier matrix (in a homogenous manner) that is rate 
controlling. For e.g. Nitro Dur – It is designed for 
application onto intact skin for 24 hrs that provide 
consistence transdermal infusion of nitroglycerine.  
2-Microreservoir partitioned controlled drug delivery 
system 
It involves dispersion of micro particles of 
suspension of drug (aqueous in nature) in a polymer using 
high energy dispersion. E.g. Syncromate implant – 
Engineered to deliver subdermal administration of 
norgestomet.  
 
B) Activation Modulated Drug Delivery System  
This type of delivery system can be achieved by  
 
1. Physical means  
 Osmotic pressure activated drug delivery system.  
 Hydrodynamic pressure controlled drug delivery 
system.  
 Vapour pressure activated drug delivery system.  
 Mechanically activated drug delivery system.  
 Magnetically activated drug delivery system.  
 Electrically activated drug delivery system.  
 Ultrasound activated drug delivery system.  
 Hydration activated drug delivery system.  
 
2. Chemical means  
 pH activated drug delivery system  
 Ion activated drug delivery system  
 Hydrolysis activated drug delivery system  
 
3-Biochemical means  
 Enzymes activated drug delivery system  
 
C) Feedback Regulated Drug Delivery System  
The release of the drug molecules from the transdermal 
system is facilitated by a agent that triggers the release of 
drug, such as biochemical in the body and also regulated by 
its concentration through some feedback mechanism.  
 Bio-erosion regulated drug delivery system.  
 Bio-responsive drug delivery system.  
 Self regulated drug delivery system.  
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D) Carrier Based Drug Delivery System  
Colloidal particulates carrier system 
This involves vesicular system like hydrogels, 
liposomes, niosomes, nanocapsules, nanoparticles, 
polymeric complexes, microspheres, nanoerythrosomes, 
transferosomes, dendrimers, aquasomes, etc.  
 
2. Basic principle of TDDS 
The skin represents an important barrier of the 
penetration of exogenous substances into the body and, on 
the other hand, a potential avenue for the transport of 
functional active principles into the skin and/or the body. 
Several studies have shown the modalities through which 
these molecules cross the horny layer, which represents the 
most important limiting factor of the process of diffusion 
and penetration, and have discussed how to increase the 
penetration of pharmacologically active substances [5-7]. 
The stratum corneum has a very peculiar structure: the 
corneocytes (the bricks: about 85% of the mass of horny 
mass) and intercellular lipids (15%) are arranged in 
approximately 15-20 layers. It consists of about 70 percent 
proteins, 15 percent lipids, and only 15 percent water. In the 
corneocytes contain keratin, filagrin, and demolition 
products. The corneocyte lacks lipids, but is rich in 
proteins. The lipids are inside extracellular spaces, in a 
bilayer organization surrounding corneocytes[8]. The very 
low permeability of the horny layer to hydrosoluble 
substances is because of this extracellular lipid matrix. 
Cutaneous penetration of hydrophilic substances is limited 
because of the convoluted and tortuous intercellular space 
and hydrophobicity of three lipidic constituents: ceramides, 
cholesterol, and free fatty acids that are present in the molar 
ratio: 1: 1: 1 (weight ratio: ceramides 50%, cholesterol 35-
40%, free fatty acids 10-15%)[9]. This ratio is critical: the 
diminution of the concentration of one of these types of 
lipids alters the molar ratio functional to the normality of 
the barrier and modifies its integrity[10]. The variations of 
this lamellar structure and/or its lipid composition are the 
structural and biochemical basis of permeability variations 
along with the thickness of the horny layer[11,12]. The 
extracellular matrix forms also the so-called reservoir of the 
horny layer (some substances are partially retained in the 
corneous layer and are slowly released).Various processes 
carried out serially or in parallel, are involved in cutaneous 
penetration of substances and these
 
may cross the stratum 
corneum via an intercellular or a transcellular route. 
Moreover, entrance through pilosebaceous units and eccrine 
glands is possible. Many efforts to obtain therapeutic 
effects in tissues far from the skin have been made. We may 
have: topical administration, with a pharmacological effect 
limited to skin, with some unavoidable systemic absorption; 
loco-regional delivery, when the therapeutic effect is 
obtained in tissues more or less deeply beneath the skin 
(muscles, articulations, vessels, etc.) with limited systemic 
absorption; and Transdermal delivery that aims to obtain, 
through application of preparations on the skin, 
pharmacologically active levels for the treatment of 
systemic diseases through skin vascular network. 
2.1 Stratum corneum barrier and intradermal delivery 
The penetration through the stratum corneum 
involves partition phenomena of applied molecules between 
lipophilic and hydrophilic compartments. For many 
substances the penetration takes place through an 
intercellular way, more than transcellular, diffusing around 
the keratinocytes. The lipid lamellae of the intercellular 
spaces (each one including 2 or 3 bilayers and made mainly 
of ceramides, cholesterol, and free fatty acids) are the 
intercellular structure of the horny layer, with the main role 
in barrier function. Most solute substances, non-polar or 
polar, penetrate across intercellular lipid avenues. The 
permeability of very polar solutes is constant and similar to 
the transport of ions (es. potassium ions). Lipophilic solute 
permeability increases according to specific lipophilic 
properties. Stratum corneum intracellular components are 
essentially devoid of lipids and lack a functional lipid 
matrix around keratin and keratohyalin. This results in an 
almost impenetrability of corneocytes[13]. Degradation of 
the corneodesmosomes causes formation of a continuous 
lacunar dominio ("aqueous pore") allowing intercellular 
penetration; the lacunae formed are scattered and not 
continuous, and form as a result of occlusion, ionophoresis, 
and ultrasound waves. These may become larger and 
connect forming a net ("pore-way"). Various methods can 
induce this type of permeability increase[14]. Transport 
through follicular and gland structures. Movement through 
hair follicles, pilosebaceous units, and eccrine glands is 
limited. The orifices of the pilosebaceous units represent 
about 10 percent in areas where their density is high (face 
and scalp) and only 0.1 percent in areas where their density 
is low. This is a possible selective way for some drugs. 
Follicular penetration may be influenced by sebaceous 
secretion, which favors the absorption of substances soluble 
in lipids. The penetration through the pilosebaceous units is 
dependent upon the property of the substance and type of 
preparation. 
a) Pharmacokinetic parameters. Vehicle / corneous 
layer partition 
For the purpose of the study of the mechanisms of 
transport and the functions of the skin barrier, it can be 
considered as a membrane or a cluster of membranes 
(mathematical principles can be applied)[15] . On the 
whole, transport through the horny layer is mainly a 
molecular passive diffusion. The physico-chemical and 
structural properties of the substance determine the capacity 
Navneet Kumar Verma et al / Advances and development in transdermal drug delivery system-A Review                                                  52 
IJAP (2017) 06 (02)                                                                                                                                          www.ssjournals.com 
of diffusion and penetration through the membrane: 
important determinants are solubility and diffusibility. The 
diffusibility and the ability of a solute to penetrate through 
the barrier is influenced by several factors including the 
tortuosity of the intercellular route. This passive process of 
absorption follows Fick's law of diffusion: the velocity of 
absorption - flow - is proportional to the difference of 
concentration of the substance in relation to that within the 
barrier. It can finally be noted that the permeability 
coefficient relates flow and concentration, resulting from 
partition coefficient, diffusion coefficient, and length of 
diffusion route [16].  
b) Role of the vehicle and excipients and interaction 
with the active principles 
A vehicle is defined by the type of preparation 
(cream, ointment, gel) and the excipients (water, paraffin, 
propylene glycol); the terms "vehicle" and "excipient" refer 
to different entities. Vehicle and excipients deeply influence 
the velocity and magnitude of absorption and consequently 
the bioavailability and efficacy. The excipients of the 
vehicle modulate the effects of partition and diffusion in the 
stratum corneum. A lipid preparation that promotes 
occlusion may enhance the penetration of the drug, but 
ointments and lipid preparations and are not always more 
powerful than creams. Creams, gels and solutions may be 
formulated so as to obtain an effect equivalent to that of 
ointments. Topical corticosteroids, of different classes of 
potency, e.g., may show the same activity when formulated 
in different vehicles[17]. A gel preparation of kellin, 
obtaining better penetration, has demonstrated important 
results in the treatment of vitiligo[18]. Also transfollicular 
penetration is influenced by vehicle and excipients; in this 
case better results are given by lipophilic and alcoholic 
vehicles. Relevant factors include dimension and charge of 
the molecules of the solute[19,20]. 
c) Conditions that modify the barrier function 
During hydration the greater part of the water is 
associated with intracellular keratin; the natural factor of 
hydration or natural moisturizing factor (NMF) absorbs a 
noticeable amount of water (10% of the weight of the 
corneocyte). Corneocytes swell and the barrier properties of 
the stratum corneum are deeply altered. In the intercellular 
space the small amount of water linked to polar groups by 
hydration does not alter the organization of lipids and does 
not reduce of permeability[21]. The effect of the hydration 
however has a discontinuous effect; the increment may be 
by ten times for some substances and very limited for 
others[22]. Occlusion partially hinders the loss of humidity 
of the skin, increasing the content of water of the horny 
layer. However the NMF level in the horny layer is almost 
zero. It seems therefore that there is a homeostatic 
mechanism that prevents hyper hydration of the skin[13]. 
Occlusion may increase the absorption by several times, 
especially for hydrophilic compounds.  
However, in some conditions it may promote the 
formation of a reservoir effect. The acidity of the cutaneous 
surface, controlling homeostasis and enzymatic activities, 
influences permeability[23]; the metabolic activity of the 
skin may modify the substances applied, influencing 
permeability and effects. Absorption is also influenced by 
other skin properties that vary at different cutaneous 
anatomical sites. For instance, the absorption diminishes 
greatly as one move from the palpebral skin to the plantar 
surfaces[24] .Age influences skin absorption. Various 
biological activities are lower in the skin of the aged 
individual. Great variation is also noted for the premature 
infant and neonate, who have greater cutaneous 
permeability[25]. There are no experimental data 
confirming the validity of friction on transcutaneous 
absorption[10]. Alterations of the barrier induce 
modifications of TEWL[13]. In addition, the horny layer 
may be defined as a biosensor; alterations of external 
humidity regulate proteolysis of filagrin, synthesis of lipids, 
DNA, and proteins within keratinocytes, which can lead 
also to inflammatory phenomena[26]. The cutaneous 
bioavailability of most commercial dermatological 
formulations is low (within 1-5% of applied dose)[27]. The 
active substances of topical formulations are generally 
absorbed in small quantities; only a reduced fraction passes 
from the vehicle into the stratum corneum. The greater part 
remains on the surface of the skin, subject to loss in several 
ways such as by sweating, chemical degradation, and 
removal. The absorption of the drug is on the order of 1-5 
percent of the applied dose. Future standards would 
therefore aim to make formulations not merely high in 
concentration, but pharmaceutically optimized to have an 
elevated (50-100%) bioavailability. On the other hand, one 
must consider the marked variations of the different 
cutaneous areas and skin conditions that make uncertain the 
therapeutic equivalence when compared with other ways of 
administration in clinical conditions [28]. 
 
3. Basic component of TDDS  
3.1 Polymer matrix / Drug reservoir 
Polymers are the backbone of TDDS, which 
control the release of the drug from the device. Polymer 
matrix can be prepared by dispersion of drug in liquid or 
solid state synthetic polymer base. Polymers used in TDDS 
should have biocompatibility and chemical compatibility 
with the drug and other components of the system such as 
penetration enhancers and PSAs. Additionally they should 
provide consistent and effective delivery of a drug 
throughout the product’s intended shelf life and should be 
of safe status[29]. Companies involved in the field of 
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transdermal delivery concentrate on a few selective 
polymeric systems. For example, Alza Corporation mainly 
concentrates on ethylene vinyl acetate (EVA) copolymers 
or micro porous polypropylene and Searle Pharmacia 
concentrates on silicon rubber[30]. Similarly Colorcon, UK 
uses HPMC for matrix preparation for propranolol 
transdermal delivery and Sigma uses ethyl cellulose for 
isosorbide dinitrate matrix[31-33]. The polymers utilized 
for TDDS can be classified as:  
Natural Polymers: e.g. cellulose derivatives, zein, gelatin, 
shellac, waxes, gums, natural rubber and chitosan etc[34]. 
Synthetic Elastomers: e.g. polybutadiene, hydrin rubber, 
polyisobutylene, silicon rubber, nitrile, acrylonitrile, 
neoprene, butyl rubber etc. 
Synthetic Polymers: e.g. polyvinyl alcohol, 
polyvinylchloride, polyethylene, polypropylene, 
polyacrylate, polyamide, polyurea, polyvinylpyrrolidone, 
polymethylmethacrylate etc. 
The polymers like cross linked polyethylene 
glycol[35], eudragits[36], ethyl cellulose, 
polyvinylpyrrolidone[37] and 
hydroxypropylmethylcellulose[38] are used as matrix 
formers for TDDS. Other polymers like EVA[39], silicon 
rubber and polyurethane[40] are used as rate controlling 
membrane.  
3.2 Drug:  
The transdermal route is an extremely attractive 
option for the drugs with appropriate pharmacology and 
physical chemistry. Transdermal patches offer much to 
drugs which undergo extensive first pass metabolism, drugs 
with narrow therapeutic window, or drugs with short half 
life which causes non- compliance due to frequent dosing. 
The foremost requirement of TDDS is that the drug 
possesses the right mix of physicochemical and biological 
properties for transdermal drug delivery[41,42]. It is 
generally accepted that the best drug candidates for passive 
adhesive transdermal patches must be non ionic, of low 
molecular weight (less than 500 Daltons), have adequate 
solubility in oil and water (log P in the range of 1-3), a low 
melting point (less than 200°C) and are potent (dose in mg 
per day)[43].  
3.3 Permeation Enhancers 
These are the chemical compounds that increase 
permeability of stratum corneum so as to attain higher 
therapeutic levels of the drug candidate[44]. Penetration 
enhancers interact with structural components of stratum 
corneum i.e., proteins or lipids. They alter the protein and 
lipid packaging of stratum corneum, thus chemically 
modifying the barrier functions leading to increased 
permeability[45]. Over the last 20 years, a tremendous 
amount of work has been directed towards the search for 
specific chemicals, combination of chemicals, which can 
act as penetration enhancers. According to the different 
categories and solvents Permeation enhancers are listed 
below. 
Permeation enhancers used for TDDS 
Solvents: Methanol[46], Ethanol [47], Dimethyl sulfoxide 
[48] Propylene glycol[49], 2- Pyrrolidone [50] Isopropyl 
myristate[51],Laurocapram (Azone)[52] 
Anionic surfactants: Sodium lauryl sulfate[53]
 
Nonionic surfactants: Sorbitan monolaurate[54], 
Pluronic[55] 
Essential oils: Cardamom oil[56], Caraway oil, Lemon 
oil[57] Menthol[58], d-limonene[59], Linoleic acid[60] 
3.4 Pressure sensitive adhesives 
A PSA is a material that helps in maintaining an 
intimate contact between transdermal system and the skin 
surface. It should adhere with not more than applied finger 
pressure, be aggressively and permanently tachy, and exert 
a strong holding force. Additionally, it should be removable 
from the smooth surface without leaving a residue[61,62]. 
Polyacrylates, polyisobutylene and silicon based adhesives 
are widely used in TDDSs[63]. The selection of an adhesive 
is based on numerous factors, including the patch design 
and drug formulation. For matrix systems with a peripheral 
adhesive, an incidental contact between the adhesive and 
the drug and penetration enhancer should not cause 
instability of the drug, penetration enhancer or the adhesive. 
In case of reservoir systems that include a face adhesive, 
the diffusing drug must not affect the adhesive. In case of 
drug-in-adhesive matrix systems, the selection will be based 
on the rate at which the drug and the penetration enhancer 
will diffuse through the adhesive. Ideally, PSA should be 
physicochemically and biologically compatible and should 
not alter drug release[64].  
3.5 Backing Laminate  
While designing a backing layer, the consideration 
of chemical resistance of the material is most important. 
Excipient compatibility should also be considered because 
the prolonged contact between the backing layer and the 
excipients may cause the additives to leach out of the 
backing layer or may lead to diffusion of excipients, drug or 
penetration enhancer through the layer. However, an 
overemphasis on the chemical resistance may lead to 
stiffness and high occlusivity to moisture vapor and air, 
causing patches to lift and possibly irritate the skin during 
long wear. The most comfortable backing will be the one 
that exhibits lowest modulus or high flexibility, good 
oxygen transmission and a high moisture vapor 
transmission rate[65,66]. Examples of some backing 
materials are vinyl, polyethylene and polyester films.  
3.6 Release Liner 
During storage the patch is covered by a protective 
liner that is removed and discharged immediately before the 
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application of the patch to skin. It is therefore regarded as a 
part of the primary packaging material rather than a part of 
dosage form for delivering the drug. However, as the liner 
is in intimate contact with the delivery system, it should 
comply with specific requirements regarding chemical 
inertness and permeation to the drug, penetration enhancer 
and water. Typically, release liner is composed of a base 
layer which may be non-occlusive (e.g. paper fabric) or 
occlusive (e.g. polyethylene, polyvinylchloride) and a 
release coating layer made up of silicon or teflon. Other 
materials used for TDDS release liner include polyester foil 
and metallized laminates[62,67]
.
 
3.7 Other excipients  
Various solvents such as chloroform, methanol, 
acetone, isopropanol and dichloromethane are used to 
prepare drug reservoir[18,68].
 
In addition plasticizers such 
as dibutylpthalate, triethylcitrate, polyethylene glycol and 
propylene glycol are added to provide plasticity to the 
transdermal patch[69,70]. 
 
4. Various methods for preparation of TDDS 
4.1 Asymmetric TPX membrane method 
A prototype patch can be fabricated for this a heat 
sealable polyester film (type 1009, 3m) with a concave of 
1cm diameter will be used as the backing membrane. Drug 
sample is dispensed into the concave membrane, covered 
by a TPX {poly (4-methyl-1 pentene)} asymmetric 
membrane, and sealed by an adhesive. [(Asymmetric TPX 
membrane preparation): These are fabricated by using the 
dry/wet inversion process. TPX is dissolved in a mixture of 
solvent (cyclohexane) and nonsolvent additives at 60°c to 
form a polymer solution. The polymer solution is kept at 
40°C for 24 hrs and cast on a glass plate to a pre-
determined thickness with a gardner knife. After that the 
casting film is evaporated at 50°C for 30 sec, then the glass 
plate is to be immersed immediately in coagulation bath 
[maintained the temperature at 25°C]. After 10 minutes of 
immersion, the membrane can be removed, air dry in a 
circulation oven at 50°C for 12 hrs[71]. 
4.2 Circular Teflon mould method 
Solutions containing polymers in various ratios are 
used in an organic solvent. Calculated amount of drug is 
dissolved in half the quantity of same organic solvent. 
Enhancers in different concentrations are dissolved in the 
other half of the organic solvent and then added. Di-N-
butylphthalate is added as a plasticizer into drug polymer 
solution. The total contents are to be stirred for 12 hrs and 
then poured into a circular teflon mould. The moulds are to 
be placed on a leveled surface and covered with inverted 
funnel to control solvent vaporization in a laminar flow 
hood model with an air speed of 0.5 m/s. The solvent is 
allowed to evaporate for 24 hrs. The dried films are to be 
stored for another 24 hrs at 25±0.5°C in a desiccators 
containing silica gel before evaluation to eliminate aging 
effects. The type films are to be evaluated within one week 
of their preparation[72].  
4.3 Mercury substrate method 
In this method drug is dissolved in polymer 
solution along with plasticizer. The above solution is to be 
stirred for 10-15 minutes to produce a homogenous 
dispersion and poured in to a leveled mercury surface, 
covered with inverted funnel to control solvent 
evaporation[73].   
4.4. By using “IPM membranes” method 
In this method drug is dispersed in a mixture of 
water and propylene glycol containing carbomer 940 
polymers and stirred for 12 hrs in magnetic stirrer. The 
dispersion is to be neutralized and made viscous by the 
addition of triethanolamine. Buffer pH 7.4 can be used in 
order to obtain solution gel, if the drug solubility in aqueous 
solution is very poor. The formed gel will be incorporated 
in the IPM membrane[74]. 
4.5 By using “EVAC membranes” method 
In order to prepare the target transdermal 
therapeutic system, 1% carbopol reservoir gel, polyethylene 
(PE), ethylene vinyl acetate copolymer (EVAC) membranes 
can be used as rate control membranes. If the drug is not 
soluble in water, propylene glycol is used for the 
preparation of gel. Drug is dissolved in propylene glycol; 
carbopol resin will be added to the above solution and 
neutralized by using 5% w/w sodium hydroxide solution. 
The drug (in gel form) is placed on a sheet of backing layer 
covering the specified area. A rate controlling membrane 
will be placed over the gel and the edges will be sealed by 
heat to obtain a leak proof device[75].  
4.6 Aluminium backed adhesive film method
 
 
Transdermal drug delivery system may produce 
unstable matrices if the loading dose is greater than 10 mg. 
Aluminium backed adhesive film method is a suitable one 
for preparation of same, chloroform is choice of solvent, 
because most of the drugs as well as adhesive are soluble in 
chloroform. The drug is dissolved in chloroform and 
adhesive material will be added to the drug solution and 
dissolved. A custammade aluminium former is lined with 
aluminium foil and the ends blanked off with tightly fitting 
cork blocks[76].  
4.7 Preparation of TDDS by using Proliposomes 
The proliposomes are prepared by carrier method 
using film deposition technique.  From the earlier reference 
drug and lecithin in the ratio of 0.1:2.0 can be used as an 
optimized one. The proliposomes are prepared by taking 
5mg of mannitol powder in a 100 ml round bottom flask 
which is kept at 60-70°c temperature and the flask is rotated 
at 80-90 rpm and dried the mannitol at vacuum for 30 
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minutes. After drying, the temperature of the water bath is 
adjusted to 20-30°C. Drug and lecithin are dissolved in a 
suitable organic solvent mixture, a 0.5ml aliquot of the 
organic solution is introduced into the round bottomed flask 
at 37°C, after complete drying second aliquots (0.5ml) of 
the solution is to be added. After the last loading, the flask 
containing proliposomes are connected in a lyophilizer and 
subsequently drug loaded mannitol powders (proliposomes) 
are placed in desiccators over night and then sieved through 
100 mesh. The collected powder is transferred into a glass 
bottle and stored at the freeze temperature until 
characterization[77,78]. 
4.8 By using free film method 
Free film of cellulose acetate is prepared by 
casting on mercury surface. A polymer solution 2% w/w is 
to be prepared by using chloroform. Plasticizers are to be 
incorporated at a concentration of 40% w/w of polymer 
weight. Five ml of polymer solution was poured in a glass 
ring which is placed over the mercury surface in a glass 
petri dish. The rate of evaporation of the solvent is 
controlled by placing an inverted funnel over the petri dish. 
The film formation is noted by observing the mercury 
surface after complete evaporation of the solvent. The dry 
film will be separated out and stored between the sheets of 
wax paper in a desiccator until use. Free films of different 
thickness can be prepared by changing the volume of the 
polymer solution[79].  
 
5. Evaluation parameters 
5.1 Interaction studies 
Excipients are integral components of almost all 
pharmaceutical dosage forms. The stability of a formulation 
amongst other factors depends on the compatibility of the 
drug with the excipients. The drug and the excipients must 
be compatible with one another to produce a product that is 
stable, thus it is mandatory to detect any possible physical 
or chemical interaction as it can affect the bioavailability 
and stability of the drug. If the excipients are new and have 
not been used in formulations containing the active 
substance, the compatibility studies play an important role 
in formulation development. Interaction studies are 
commonly carried out in Thermal analysis, FT-IR, UV and 
chromatographic techniques by comparing their 
physicochemical characters such as assay, melting 
endotherms, characteristic wave numbers, absorption 
maxima etc.
 
[80,81] 
5.2 Thickness of the patch 
The thickness of the drug loaded patch is measured 
in different points by using a digital micrometer and 
determines the average thickness and standard deviation for 
the same to ensure the thickness of the prepared patch[82].   
 
5.3 Weight uniformity 
The prepared patches are to be dried at 60°C for 
4hrs before testing. A specified area of patch is to be cut in 
different parts of the patch and weigh in digital balance. 
The average weight and standard deviation values are to be 
calculated from the individual weights[82]. 
5.4 Folding endurance 
A strip of specific are is to be cut evenly and 
repeatedly folded at the same place till it broke. The 
number of times the film could be folded at the same place 
without breaking gave the value of the folding 
endurance[82]. 
5.5 Percentage Moisture content 
The prepared films are to be weighed individually 
and to be kept in a desiccator containing fused calcium 
chloride at room temperature for 24 hrs. After 24 hrs the 
films are to be reweighed and determine the percentage 
moisture content from the below mentioned formula[82].                   
Percentage moisture content = [Initial weight- Final weight/ 
Final weight] ×100. 
5.6 Percentage Moisture uptake 
The weighed films are to be kept in a desiccator at 
room temperature for 24 hrs containing saturated solution 
of potassium chloride in order to maintain 84% RH.  After 
24 hrs the films are to be reweighed and determine the 
percentage moisture uptake from the below mentioned 
formula
 
[58].                   
Percentage moisture uptake = [Final weight- Initial weight/ 
initial weight] ×100. 
5.7 Water vapour permeability (WVP) evaluation 
Water vapour permeability can be determined with 
foam dressing method the air forced oven is replaced by a 
natural air circulation oven. The WVP can be determined 
by the following formula  
WVP=W/A 
Where, WVP is expressed in gm/m2 per 24hrs, 
W is the amount of vapour permeated through the 
patch expressed in gm/24hrs and A is the surface area of the 
exposure samples expressed in m
2
[83] 
5.8 Drug content 
A specified area of patch is to be dissolved in a 
suitable solvent in specific volume. Then the solution is to 
be filtered through a filter medium and analyse the drug 
contain with the suitable method (UV or HPLC technique). 
Each value represents average of three different 
samples[83]. 
5.9 Uniformity of dosage unit test 
An accurately weighed portion of the patch is to be 
cut into small pieces and transferred to a specific volume 
volumetric flask, dissolved in a suitable solvent and 
sonicate for complete extraction of drug from the patch and 
made up to the mark with same.  The resulting solution was 
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allowed to settle for about an hour, and the supernatant was 
suitably diluted to give the desired concentration with 
suitable solvent. The solution was filtered using 0.2cm 
membrane filter and analysed by suitable analytical 
technique (UV or HPLC) and the drug content per piece 
will be calculated[84]. 
5.10 Polariscope examination 
This test is to be performed to examine the drug 
crystals from patch by polariscope. A specific surface area 
of the piece is to be kept on the object slide and observe for 
the drugs crystals to distinguish whether the drug is present 
as crystalline form or amorphous form in the patch[84]. 
5.11 Shear Adhesion test 
This test is to be performed for the measurement 
of the cohesive strength of an adhesive polymer.  It can be 
influenced by the molecular weight, the degree of cross 
linking and the composition of polymer, type and the 
amount of tackifier added.  An adhesive coated tape is 
applied onto a stainless steel plate; a specified weight is 
hung from the tape, to affect it pulling in a direction parallel 
to the plate.  Shear adhesion strength is determined by 
measuring the time it takes to pull the tape off the plate. 
The longer the time take for removal, greater is the shear 
strength[84].  
5.12 Peel Adhesion test 
In this test, the force required to remove an 
adhesive coating form a test substrate is referred to as peel 
adhesion.  Molecular weight of adhesive polymer, the type 
and amount of additives are the variables that determined 
the peel adhesion properties. A single tape is applied to a 
stainless steel plate or a backing membrane of choice and 
then tape is pulled from the substrate at a 180º angle, and 
the force required for tape removed is measured[84]. 
5.13 Thumb tack test 
It is a qualitative test applied for tack property 
determination of adhesive.  The thumb is simply pressed on 
the adhesive and the relative tack property is detected[84].  
5.14 Flatness test 
Three longitudinal strips are to be cut from each 
film at different portion like one from the center, other one 
from the left side, and another one from the right side. The 
length of each strip was measured and the variation in 
length because of non-uniformity in flatness was measured 
by determining percent constriction, with 0% constriction 
equivalent to 100% flatness[85]. 
5.15 Percentage Elongation break test 
The percentage elongation break is to be 
determined by noting the length just before the break point, 
the percentage elongation can be determined from the 
below mentioned formula   
Elongation percentage = L1-L2   ×100 
 L2 
Where, L1is the final length of each strip and L2 is the 
initial length of each strip[86].      
5.16 Rolling ball tack test 
This test measures the softness of a polymer that 
relates to talk.  In this test, stainless steel ball of 7/16 inches 
in diameter is released on an inclined track so that it rolls 
down and comes into contact with horizontal, upward 
facing adhesive.  The distance the ball travels along the 
adhesive provides the measurement of tack, which is 
expressed in inch[87]. 
5.17 Quick Stick (peel-tack) test 
In this test, the tape is pulled away from the 
substrate at 90ºC at a speed of 12 inches/min.  The peel 
force required breaking the bond between adhesive and 
substrate is measured and recorded as tack value, which is 
expressed in ounces or grams per inch width[87]. 
5.18 Probe Tack test 
In this test, the tip of a clean probe with a defined 
surface roughness is brought into contact with adhesive, 
and when a bond is formed between probe and adhesive.  
The subsequent removal of the probe mechanically breaks 
it.  The force required to pull the probe away from the 
adhesive at fixed rate is recorded as tack and it is expressed 
in grams[87].    
5.19 In vitro drug release studies 
The paddle over disc method (USP apparatus V) 
can be employed for assessment of the release of the drug 
from the prepared patches. Dry films of known thickness is 
to be cut into definite shape, weighed, and fixed over a 
glass plate with an adhesive. The glass plate was then 
placed in a 500-mL of the dissolution medium or phosphate 
buffer (pH 7.4), and the apparatus was equilibrated to 32± 
0.5°C. The paddle was then set at a distance of 2.5 cm from 
the glass plate and operated at a speed of 50 rpm. Samples 
(5-mL aliquots) can be withdrawn at appropriate time 
intervals up to 24 h and analyzed by UV spectrophotometer 
or HPLC. The experiment is to be performed in triplicate 
and the mean value can be calculated[80]. 
5.20 In vitro skin permeation studies 
An in vitro permeation study can be carried out by 
using diffusion cell. Full thickness abdominal skin of male 
Wistar rats weighing 200 to 250g.  Hair from the abdominal 
region is to be removed carefully by using a electric clipper; 
the dermal side of the skin was thoroughly cleaned with 
distilled water to remove any adhering tissues or blood 
vessels, equilibrated for an hour in dissolution medium or 
phosphate buffer pH 7.4 before starting the experiment and 
was placed on a magnetic stirrer with a small magnetic 
needle for uniform distribution of the diffusant. The 
temperature of the cell was maintained at 32 ± 0.5°C using 
a thermostatically controlled heater. The isolated rat skin 
piece is to be mounted between the compartments of the 
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diffusion cell, with the epidermis facing upward into the 
donor compartment.  Sample volume of definite volume is 
to be removed from the receptor compartment at regular 
intervals, and an equal volume of fresh medium is to be 
replaced. Samples are to be filtered through filtering 
medium and can be analyzed spectrophotometrically or 
HPLC. Flux can be determined directly as the slope of the 
curve between the steady-state values of the amount of drug 
permeated (mg cm-2) vs. time in hours and permeability 
coefficients were deduced by dividing the flux by the initial 
drug load (mg cm-2)
 
[80]. 
5.21 Skin Irritation study 
Skin irritation and sensitization testing can be 
performed on healthy rabbits (average weight 1.2 to 1.5 kg). 
The dorsal surface (50cm2) of the rabbit is to be cleaned 
and remove the hair from the clean dorsal surface by 
shaving and clean the surface by using rectified spirit and 
the representative formulations can be applied over the 
skin. The patch is to be removed after 24 hr and the skin is 
to be observed and classified into 5 grades on the basis of 
the severity of skin injury[84]. 
5.22 Stability studies 
Stability studies are to be conducted according to 
the ICH guidelines by storing the TDDS samples at 
40±0.5°c and 75±5% RH for 6 months. The samples were 
withdrawn at 0, 30, 60, 90 and 180 days and analyze 
suitably for the drug content[80]. 
 
6. Advance development in TDDS 
Figure 2: Global Transdermal Drug Delivery Product 
sales by segment 
Drug in adhesive technology has become the 
preferred system for passive transdermal delivery; two 
areas of formulation research are focused on adhesives and 
excipients. Adhesive research focuses on customizing the 
adhesive to improve skin adhesion over the wear period, 
improve drug stability and solubility, reduce lag time, and 
increase the rate of delivery. Because a one-size-fits-all 
adhesive does not exist that can accommodate all drug and 
formulation chemistries, customizing the adhesive 
chemistry allows the transdermal formulator to optimize the 
performance of the transdermal patch.
 
[36] 
6.1 Transdermal Drug Delivery System Market
, 
 
A list of companies gives transdermal drug 
delivery systems with their current products and 
technologies in the market. 3M Pharmaceuticals is a leader 
in pioneering the technological components in transdermal 
drug delivery system and components made by 3M are used 
for manufacturing the complete spectrum of drugs delivered 
transdermally. Figure 6 shows a graph showing the range of 
transdermal drug delivery system currently sold in the 
market. On the X-axis are the drugs that are administered 
transdermally, while the Y-axis in the graph shows 
percentage of the total transdermal products that are being 
sold in the market.  
 
 
Figure 3: Graph of Transdermal Drug Delivery 
Products Vs. Percentage Total Sold Transdermal Drug 
Delivery Products. 
 
The range of the current drugs that are 
administered by using Transdermal drug delivery technique 
is still limited due to the skin posing as a barrier against the 
drug diffusion or permeation[88].  
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Table 1: Companies and their Transdermal Drug Delivery Technologies & Products 
Company Name Transdermal Products/Technology in Market 
3M Pharmaceuticals MinitranTM, Pioneer in the field of Manufacturing Transdermal Components 
Acrux Ltd. ACROSSR, MDTSR, Patchless PatchR 
Adhesives Research, Inc ETATM, HRT Adhesives, PIB Adhesives, MTT Adhesives 
Adherex Technologies, Inc. Exherin
TM
 
Altea Therapeutics Corp. PassPort
R
 Patch 
Alza Corp. D-Trans
R
 System, E-Trans
R
 System, Macroflux
R
 System 
Antares Pharma, Inc. ATD
TM 
Gel Technology 
Biochemics, Inc. PEN to CORER 
Boehringer Ingelheim Corp. CATAPRES-T
TSR
 
Dermisonics, Inc. U-Strip 
Elan Transdermal Technologies, Inc. Buspirone Patch 
Inovio Biomedical Corp. MedPulser Electroporation Therapy System 
ImaRx Therapeutics, Inc. SonoDerm
TM
 Technology 
Iomed, Inc. Iontophoreris Electrodes: Trans
QR
 Flex, IOGELR, Trans
QR
 E, 
Optima
AR
 ; Numby Stuff 
R
, IONTOCAINER, Phoresor
R
 
Noven Pharmaceuticals, Inc. Vivelle
R
, Vivelle-Dot
TM
, Combi Patch
TM
, Estalis 
R
, Methy Patch
R
 
L.A.M. Pharmaceuticals LLC IPM Wound Gel
TM
, Polymer Matrix
TM
 Technology 
Macrochem Corp. MacroDerm
TM
, SEPAR 
Norwood Abbey Ltd. Laser Assisted Drug Delivery(LAD), Micro-needle Drug Delivery 
Sontra Medical Corp. SonoPrep
R
 
Travanti Pharma, Inc. Wearable Electronic Disposable Drug (WEDDR) 
Vyteris, Inc. LidoSite
TM
 Topical System 
 
This barrier of stratum corneum is overcome by 
use of active transdermal drug delivery techniques that are 
relatively new to the market but are considered to have 
great potential towards increasing the range and variety of 
drugs that could be administered transdermally. The annual 
market for transdermal Drug Delivery systems is more than 
$3 billion.[89] 
6.2 FDA Regulation and Transdermal Drug Delivery 
System 
The first FDA approved Transdermal Drug Patch 
was in the year 1979.[90]
 
Since then, the transdermal drug 
delivery systems have come a long way. A chronology was 
given by the events in the field of transdermal technology 
along with the approvals that were obtained at every stage 
of this chronology. The FDA regulation process for 
Transdermal drug delivery system is very stringent. 
Transdermal Drug Delivery system is a combinational 
device as defined in 21 CFR § 3.2(e) by Food and Drug 
Administration.[91,92]  Transdermal drug delivery system 
have to undergo premarket approval (PMA) and hence 
requires substantial evidence including biomechanical 
testing, animal testing, clinical trials studies before the 
transdermal patch can get approval for use in the market. 
The most recent approval in the field of transdermal drug 
delivery system was the approval of Nuepro patch for 
treatment of Parkinson’s disease.[93] In the case of Passive 
transdermal drug delivery system, the factor that requires 
consideration is ensuring that the drug in the drug-reservoir 
or the drug-in-adhesive is present and being delivered in a 
stable as well as controlled form.[94] It is also important to 
understand the reactivity of the drug on the skin and ensure 
that the material used for manufacturing the transdermal 
patch do not have an adverse reaction on the skin, for 
instance itching, inflammation, etc. The patch also needs to 
be kept on from several hours to, in some cases, several 
days (e.g., contraceptive patch) and hence the properties of 
the patch like the type of polymers, adhesives used in the 
making also need special consideration. The material used 
for making the patch is polymers. There are various types 
of polymeric materials that are utilized for the construction 
of transdermal drug delivery system. The following section 
in the paper describes the polymeric materials along with 
their properties that are used in the making of transdermal 
drug delivery system.  
6.3 The Future of Transdermal Drug Delivery  
The statical data showed a market of $ 12.7 billion 
in the year 2005 which is assumed to increase by $ 21.5 
billion in the year 2010 and $ 31.5 billion in the year 2015. 
Almost all the pharmaceutical companies are developing 
TDDS[95]. TDDS may be ideal for many injected as well 
as orally given drugs, but many drugs cannot penetrate the 
skin membrane effectively because of low permeability of 
skin barrier. Pharmaceutical companies are now developing 
new adhesives, substances that enhance molecular 
absorption as well as penetration that will ultimately affect 
skin permeation and greatly increase the list of drugs which 
can be delivered transdermally. Well known technologies 
that are iontophoresis and phonophoresis (sonophoresis) 
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considered to achieve significant plasma concentration 
levels via skin membrane. A micro needle technology is 
more promising for drug administered via skin. These 
systems use an arrangement of small needle-like structures 
to open pores in the stratum cornea and facilitate drug 
transport without any sensation of pain because these are 
not reachable to nerve endings. These systems are reported 
to greatly enhance the permeability of macromolecules 
across skin.[96]  
 
7. Conclusion 
Transdermal drug delivery systems have been used 
as rational drug therapy (safe, effective and economic) drug 
delivery devices. Due to large advantages of the TDDS, 
many new researches are going on in the present day to 
incorporate newer drugs via the system. A transdermal 
patch has several basic components like drug reservoirs, 
liners, adherents, permeation enhancers, backing laminates, 
plasticizers and solvents, which play a vital role in the 
release of drug via skin. Different methods are used to 
prepare these patches by using basic components of TDDS. 
After preparation of transdermal patches, they are evaluated 
for physicochemical studies, in vitro permeation studies, 
skin irritation studies and stability studies. But all prepared 
and evaluated transdermal patches must receive approval 
from FDA before sale. Future developments of TDDSs will 
likely focus on the increased control of therapeutic 
regimens and the continuing expansion of drugs available 
for use. Transdermal dosage forms may provide clinicians 
an opportunity to offer more therapeutic options to their 
patients to optimize their care.  
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